1st Feb 2012
GSK has released a statement in regards to price reductions of F2 medicines:
GlaxoSmithKline (GSK) Australia will reduce the price of F2 medicines impacted by the price disclosure reduction on 1 March 2012, one month earlier than the Government requirement, to assist pharmacists and minimise any possible disruption to patient access to medicines.
The introduction of mandatory price disclosure for all medicines listed on the F2 formulary (both new and existing listed drugs) was included as part of the MOU between Medicines Australia and the Australian Government. As a result a price disclosure reduction was applied to a number of medicines on the PBS to take effect from 1 April 2012.
GSK medicines affected are Amoxil (amoxycillin), Aropax (paroxetine), Augmentin (amoxyxcillin and clavulanic acid), Avandamet (rosiglitazone & metformin) and Lamictal (lamotrigine).
“To minimise the risk of an interruption to patient access to our medicines affected by the 1 April price cut, GSK is offering pharmacists a price reduction one month prior, to assist with stock management,” David Herd, Director Healthcare Environment said.
“We are committed to increasing access to our medicines and vaccines. By striving to meet society’s healthcare needs, we build trust in our business,” Mr Herd said.
For full content of newsletter, please click: